Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors are optimistic about Accuray's (ARAY) solid product portfolio.

Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?

Data Highlight Expanding Use of (Ultra) Hypofractionated Treatments, Benefits in Patient Care Made Possible by the Precision and Accuracy of Accuray Technologies SUNNYVALE, Calif. , May 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife ® and TomoTherapy ® platforms, including the latest generation Radixact ® System.

Accuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems' Versatility, Efficiency and Effectiveness

Accuray grew revenue by 22.8% year over year in its fiscal 2023 third quarter. The company had its first quarter of positive net income since its fiscal 2022 second quarter.

Why Shares of Accuray Rose Thursday

Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.

Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates

Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Accuray (ARAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Accuray Incorporated (ARAY) Q3 2023 Earnings Call Transcript.

Accuray Incorporated (ARAY) Q3 2023 Earnings Call Transcript

Accuray (ARAY) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.01 per share a year ago.

Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates

Company delivers record quarterly revenue and unit volume in Q3; Reiterates fiscal year guidance SUNNYVALE, Calif. , April 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter of fiscal 2023 ended March 31, 2023.

Accuray Reports Fiscal 2023 Third Quarter Financial Results

SUNNYVALE, Calif. , April 13, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2023, ended March 31, 2023, during a conference call hosted by company management at 1:30 p.m.

Accuray to Report Third Quarter Fiscal 2023 Financial Results on April 26, 2023

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

CRISPR Therapeutics

Illumina

Healthcare costs in America and the world are set to rise in the foreseeable future. All thanks to an aging population, and the expectation that healthcare companies will be able to cure more of our diseases.

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time

Company to Take Part in Fireside Chat Tuesday, March 14, 2023 at 1:00pm PST / 4:00pm EST SUNNYVALE, Calif. , March 8, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 33rd Annual Oppenheimer Healthcare Conference taking place March 13-15, 2023.

Accuray Incorporated to Speak at 33rd Annual Oppenheimer Healthcare Conference

Company to Take Part in Fireside Chat Monday, March 6, 2023 at 10:30am PST / 1:30pm EST SUNNYVALE, Calif. , Feb. 21, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Cowen 43rd Annual Health Care Conference taking place March 6-8, 2022.

Accuray to Participate in the Cowen 43rd Annual Health Care Conference

SUNNYVALE, Calif. , Feb. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023.

Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.

Accuray (ARAY) Q2 Earnings and Revenues Top Estimates

The radiation-oncology machine company saw shares rise after it released an earnings report.

Why Shares of Accuray Jumped Thursday

Accuray's revenue did fall year-over-year as reported, but the company beat expectations and product revenue reached a new all-time high with 8% year-over-year constant-currency growth. Orders grew sequentially at a double-digit rate and net orders doubled; Accuray still has work to do to reach $100M in gross quarterly orders.

Accuray Achieves Record Product Revenue, But There's Much Work Still To Be Done

Accuray Incorporated (NASDAQ:ARAY ) Q2 2023 Earnings Conference Call February 1, 2023 4:30 PM ET Company Participants Jesse Chew - Senior Vice President, General Counsel & Corporate Secretary Suzanne Winter - Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Josh Jennings - Cowen Neil Chatterji - B. Riley Brooks O'Neil - Lake Street Capital Markets Jason Wittes - Loop Capital Operator Good day and welcome to the Accuray Second Quarter Fiscal 2023 Financial Results.

Accuray Incorporated (ARAY) Q2 2023 Earnings Call Transcript

Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates

SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Robert C.

Robert C. Kill Joins Accuray Board of Directors

Delivered strong Q2 performance amidst challenging macroenvironment; Reiterate fiscal year guidance     SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2023 ended December 31, 2022.

Accuray Reports Fiscal 2023 Second Quarter Financial Results

Center believes the CyberKnife System is the #1 tool for delivery of advanced radiosurgery treatments Selected the latest generation CyberKnife S7™ System to increase the number of indications they can treat throughout the body, and the patients they can help SUNNYVALE, Calif. , Jan. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the European Radiosurgery Center Munich has selected a second CyberKnife ® System, the latest generation CyberKnife S7™ System, to enable their team to treat the high volume of patients they see in their practice who would benefit from the extremely precise radiation treatments it delivers.

European Radiosurgery Center Munich Invests in Second Accuray CyberKnife® System to Support the Demand for High-Precision Radiosurgery Treatments

SUNNYVALE, Calif. , Jan. 18, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2023, ended December 31, 2022, after the market close on February 1, 2023.

Accuray to Report Second Quarter Fiscal 2023 Financial Results on February 1, 2023

Auckland Radiation Oncology Selected the Latest-Generation CyberKnife S7™ System to Deliver Precise Treatments More Quickly, so Patients Can Rapidly Return to the Activities They Enjoy SUNNYVALE, Calif. , Jan. 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Auckland Radiation Oncology (ARO) is the first center in New Zealand to treat patients with the CyberKnife ® System, a robotic radiation therapy device known for delivering treatments with sub-millimeter precision and accuracy in typically 1 to 5 outpatient sessions.

Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device

Company to Take Part in Fireside Chat Wednesday, January 18, 2023 at 7:00am PST/10:00am EST SUNNYVALE, Calif. , Jan. 10, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the B.

News for Accuray Stock (ARAY)